Neurocrine’s $2.9bn Soleno deal raises the stakes in Prader-Willi syndrome treatment
Find out how Neurocrine’s $2.9bn Soleno acquisition could reshape VYKAT XR’s rare disease launch strategy.
What BridgeBio Pharma, Inc.’s latest data signals for the future of targeted endocrine therapies
Explore how BridgeBio Pharma, Inc.’s Phase 3 CALIBRATE data could transform ADH1 treatment and reshape rare endocrine care. Read more now.
Harbour BioMed converts SPR202 partnership into strategic stake in Spruce Biosciences
Harbour BioMed acquires stake in Spruce Biosciences, reinforcing its SPR202 collaboration. Find out what this signals for CRH-targeted therapies.
Innovent’s mazdutide earns Nature spotlight: Are dual GCG/GLP-1 agonists set to reshape diabetes and obesity care?
Innovent Biologics, Inc. has achieved a landmark moment in China’s clinical research trajectory with the back-to-back publication of two Phase 3 clinical trials of mazdutide, a dual GCG/GLP-1 receptor agonist, in Nature as Accelerated Article Previews. These studies, known as DREAMS-1 and DREAMS-2, evaluated the drug as monotherapy and as an add-on therapy in Chinese […]